Guanidino phenylalanin compounds used as urokinase inhibitors

1. A method of treating pancreatic or mammary carcinoma, which comprises administering to a human or animal in need thereof, an effective amount of a compound of formula I

which are present as racemates or as D- or L-configured compounds and in which R 1

(f) is a group of the formula

in which R 8

(i) is an optionally substituted C 1 -C 6 -alkyl radical or aryl radical,

(ii) is a saturated or unsaturated, branched or unbranched C 1 -C 6 -alkoxy radical,

(iii) is an optionally substituted oxycarbonyl radical e.g. an ethoxycarbonyl, phenoxycarbonyl or benzyloxycarbonyl radical, or

(iv) is an optionally substituted aminocarbonyl radical, e.g. an ethyl-aminocarbonyl radical,

R 2 is an optionally substituted phenyl radical,

R 3 is H or branched or unbranched C 1 -C 4 -alkyl and n is 0 or 1,

Z is N or CR 9, where R 9 is H or branched or unbranched C 1 -C 4 -alkyl, or pharmaceutically acceptable salts thereof.

2. The method of claim 1 , characterized in that R 1 is a group of the formulae (b), (d) and (f), R 2 is a 2,4,6-triisopropylphenyl radical and n=O.

3. The method of claim 1 , characterized in that the compound of the formula I is Nα-(2,4,6-triisopropylphenylsulfonyl)-3-guanidino-(D,L)- phenylalanine-4-ethoxycarbonyl piperazide, Nα-(2,4, 6-triisopropyl phenylsulfonyl)-3- guanidino-(D,L)-phenylalanine-4-ethylaminocarbonyl piperazide, or the L-enantiomer or a pharmaceutically tolerated salt of one of the compounds.

4. The method of claim 1 , characterized in that the compound is present in the form of a physiologically tolerated acid salt.

5. The method of claim 1 , characterized in that the compounds of formula I are employed as conjugates with other pharmacologically active substances.

6. The method of claim 1 , characterized in that the compounds of formula I are employed in combination with other pharmacologically active substances.

7. The method of claim 5 , characterized in that the compounds are employed as conjugates with radiolabels and/or in combination with cytotoxic substances.

8. The method of claim 1 , in which the compound is administered orally, topically, rectally or parenterally.

9. The method of claim 1 , in which the compound is administered in the form of a tablet, a sugar-coated tablet, a capsule, a pellet, a suppository, a solution or a transdermal system such as a plaster.

10. The method of claim 4 , wherein the acid salt is the hydrocholoride salt.

11. A compound of the formula I

in which R 1 , R 3 , Z and n are defined as in claim 1 , and R 2 comprises a tri-substituted phenyl radical.

12. Nα-(2, 4, 6-triisopropyl phenylsulfonyl)-3-guanidino-(D, L)-phenylalanine-4-ethoxycarbonyl piperazide, Nα-(2,4,6-triisopropylphenylsulfonyl)-3-guanidino-(D,L)-phenylalanine-4-ethylaminocarbonyl piperazide or the L-enantiomer thereof, or a pharmaceutically tolerated salt of one of the compounds.

13. A pharmaceutical composition, characterized in that it comprises, as active compound, one or more compounds as claimed in claim 11 , where appropriate together with pharmaceutically customary excipients, adjuvants and/or diluents.

14. The compound of claim 11 , wherein the substituents on the R 2 tri-substituted phenyl radical are independently C 1 -C 6 alkyl, C 1 -C 3 alkoxy, hydroxyl, carboxyl, sulfonyl, nitro, cyano, oxo or halogen.

15. The compound of claim 11 , wherein R 2 is a 2,4,6-trisubstituted phenyl radical.